AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells
作者： Ting-Jing Yao , Jin-Hai Zhu , De-Feng Peng , Zhen Cui , Chao Zhang
DOI: 10.1007/S13277-015-3237-1
关键词:
摘要: Colorectal cancer (CRC) causes significant mortalities worldwide. Fibroblast growth factor (FGF) receptor (FGFR) signaling is frequently dysregulated and/or constitutively activated in CRCs, contributing to carcinogenesis and progression. Here, we studied the activity of AZD-4547, a novel potent FGFR kinase inhibitor, on CRC cells. AZD-4547 inhibited cell vitro, its correlated with FGFR-1/2 expression level. was cytotoxic pro-apoptotic FGFR-1/2-expressed lines (NCI-H716 HCT-116), but not null HT-29 Further, cycle progression attenuated activation FGFR1-FGFR substrate 2 (FRS-2), ERK/mitogen-activated protein (MAPK), AKT/mammalian target rapamycin (AKT/mTOR) signalings NCI-H716 HCT-116 In vivo, oral administration at effective doses (high expression) xenograft nude mice. Phosphorylation FGFR-1, AKT, ERK1/2 specimens also by administration. Thus, our preclinical studies strongly support possible clinical investigations for treatment CRCs harboring deregulated signalings.
springer.com
sci-hub.se 参考文章(31)
Masaru Katoh, Hitoshi Nakagama, FGF receptors: cancer biology and therapeutics. Medicinal Research Reviews. ,vol. 34, pp. 280- 300 ,(2014) , 10.1002/MED.21288
Lindsey A. Allan, Nick Morrice, Suzanne Brady, Gareth Magee, Shalini Pathak, Paul R. Clarke, Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK Nature Cell Biology. ,vol. 5, pp. 647- 654 ,(2003) , 10.1038/NCB1005
Min-Bin Chen, Xiao-Yang Wu, Jin-Hua Gu, Qing-Tao Guo, Wen-Xiang Shen, Pei-Hua Lu, Activation of AMP-Activated Protein Kinase Contributes to Doxorubicin-Induced Cell Death and Apoptosis in Cultured Myocardial H9c2 Cells Cell Biochemistry and Biophysics. ,vol. 60, pp. 311- 322 ,(2011) , 10.1007/S12013-011-9153-0
J B Easton, P J Houghton, mTOR and cancer therapy. Oncogene. ,vol. 25, pp. 6436- 6446 ,(2006) , 10.1038/SJ.ONC.1209886
Nicholas Turner, Richard Grose, Fibroblast growth factor signalling: from development to cancer. Nature Reviews Cancer. ,vol. 10, pp. 116- 129 ,(2010) , 10.1038/NRC2780
Ahmad D. Siddiqui, Bilal Piperdi, KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy Annals of Surgical Oncology. ,vol. 17, pp. 1168- 1176 ,(2010) , 10.1245/S10434-009-0811-Z
Amanda K. Arrington, Eileen L. Heinrich, Wendy Lee, Marjun Duldulao, Supriya Patel, Julian Sanchez, Julio Garcia-Aguilar, Joseph Kim, Prognostic and predictive roles of KRAS mutation in colorectal cancer. International Journal of Molecular Sciences. ,vol. 13, pp. 12153- 12168 ,(2012) , 10.3390/IJMS131012153
Marie Westwood, Thea van Asselt, Bram Ramaekers, Penny Whiting, Manuela Joore, Nigel Armstrong, Caro Noake, Janine Ross, Johan Severens, Jos Kleijnen, KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis Health Technology Assessment. ,vol. 18, pp. 1- 132 ,(2014) , 10.3310/HTA18620
S. H. Ong, Y. R. Hadari, N. Gotoh, G. R. Guy, J. Schlessinger, I. Lax, Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 98, pp. 6074- 6079 ,(2001) , 10.1073/PNAS.111114298
Adel H Jebar, Carolyn D Hurst, Darren C Tomlinson, Colin Johnston, Claire F Taylor, Margaret A Knowles, None, FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma Oncogene. ,vol. 24, pp. 5218- 5225 ,(2005) , 10.1038/SJ.ONC.1208705